MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. (Nasdaq: SEPR) today announced the publication of results from its Phase IIIB/IV, 410-patient, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of LUNESTA® brand eszopiclone for the treatment of insomnia in perimenopausal and menopausal women suffering from insomnia. The results of this study were published in the December 2006 issue of the Journal of Obstetrics and Gynecology.
